The Life Sciences Report
Notable Quotes
"Behind Omidria, OMER has a robust pipeline that has advanced into a number of phase 1 and phase 2 trials." (3/6/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico More >
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More >
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >
"ACRX has a revolutionary painkiller, Zalviso; the stock is a very good buy, with lots of upside." (2/20/14) AcelRx Pharmaceuticals Inc. - The Life Sciences Report Interview with Chen Lin More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
VentriPoint Inc.TICKER: VPT:TSX.V
|